{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:49:27Z","timestamp":1782604167237,"version":"3.54.5"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Kimura disease (KD) is a rare and benign chronic inflammatory disease of unknown cause. It is characterized by subcutaneous granuloma of soft tissues in the head and neck region, increased eosinophil count, and elevated serum IgE. Currently, no definitive treatments are recommended. A 57-year-old Chinese man was diagnosed with KD after 7 years of slow subcutaneous masses growth. The patient underwent treatment of oral glucocorticoids for 1 year, but the masses recurred as the dosage was tapered down. Subsequent anti-IgE therapy of omalizumab administered subcutaneously at 450 mg\/day at a 4-week interval did not show improvement. The size of masses and serum IgE and circulating eosinophils did not decrease significantly after 19 cycles of continuous treatment. Ultimately, switched strategy of dupilumab was applied at an initial dose of 600 mg, followed by 300 mg every 2 weeks for 4 months. This treatment demonstrated dramatical effects with reduced masses in each area and fast dropdown of eosinophil counts, while the high level of serum IgE remained without changes. Recently, different biologics including anti-IgE, anti-IL-5, and anti-IL-4\/IL-13 have been applied to treat KD with satisfied results and help to explore the pathogenesis of this rare disease. To our knowledge, this is the first report that demonstrates the effects of two different biologics in the same patient and reveals the impressive clinical efficacy of dupilumab to treat KD independent of IgE. Therefore, further investigation of the underlying mechanism and the development of diagnosis and treatment of KD is valuable.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1084879","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T07:46:40Z","timestamp":1671004000000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Successful treatment of dupilumab in Kimura disease independent of IgE: A case report with literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Boyun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyue","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wo","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuya","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620718780370","article-title":"A case series of kimura's disease: A diagnostic challenge","volume":"9","author":"Kumar","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcms.2009.08.001","article-title":"Head and neck lesions of kimura's disease: exclusion of human herpesvirus-8 and Epstein-Barr virus by in situ hybridisation and polymerase chain reaction. an immunohistochemical study","volume":"38","author":"Pitak-Arnnop","year":"2010","journal-title":"J Craniomaxillofac Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198811000-00005","article-title":"Kimura's disease. Involvement of regional lymph nodes and distinction from angiolymphoid hyperplasia with eosinophilia","volume":"12","author":"Kuo","year":"1988","journal-title":"Am J Surg Pathol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/00313028409067909","article-title":"Kimura's disease: A clinico-pathological study of 21 cases and its distinction from angiolymphoid hyperplasia with eosinophilia","volume":"16","author":"Kung","year":"1984","journal-title":"Pathology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12882-018-1123-y","article-title":"Nephrotic syndrome associated with kimura's disease: a case report and literature review","volume":"19","author":"Ren","year":"2018","journal-title":"BMC Nephrol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5858\/2007-131-650-KD","article-title":"Kimura disease","volume":"131","author":"Abuel-Haija","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0194-5998(95)70259-8","article-title":"Treatment of kimura's disease: A therapeutic enigma","volume":"112","author":"Day","year":"1995","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12893-019-0673-7","article-title":"Clinical analysis of kimura's disease in 24 cases from China","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2011.12.002","article-title":"Treatment of kimura disease with photodynamic therapy: a case study","volume":"9","author":"Abbas","year":"2012","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12890-022-02094-9","article-title":"Concurrence of IgG4-related disease and kimura disease with pulmonary embolism and lung cancer: A case report","volume":"22","author":"Lu","year":"2022","journal-title":"BMC Pulm Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/his.14428","article-title":"A comparative study of kimura's disease and IgG4-related disease: Similarities, differences and overlapping features","volume":"79","author":"Wang","year":"2021","journal-title":"Histopathology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.ijom.2020.05.023","article-title":"Differential diagnosis of immunoglobulin G4-related sialadenitis and kimura's disease of the salivary gland: A comparative case series","volume":"50","author":"Zhu","year":"2021","journal-title":"Int J Oral Maxillofac Surg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.anl.2010.03.011","article-title":"Increase of Th2 and Tc1 cells in patients with kimura's disease","volume":"38","author":"Ohta","year":"2011","journal-title":"Auris Nasus Larynx."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2016-204096","article-title":"Expression of the interleukin-21 and phosphorylated extracellular signal regulated kinase 1\/2 in kimura disease","volume":"70","author":"Chen","year":"2017","journal-title":"J Clin Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2017.7.4.221","article-title":"Basophils are increased and express increased levels of interleukin-4 in the parotid lesions of kimura disease","volume":"7","author":"Nonaka","year":"2017","journal-title":"Asia Pac Allergy"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018300","article-title":"Tissue-infiltrating immune cells contribute to understanding the pathogenesis of kimura disease: A case report","volume":"98","author":"Maehara","year":"2019","journal-title":"Med (Baltimore)."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2013.12.006","article-title":"Anti-IgE therapy to kimura's disease: a pilot study","volume":"41","author":"Nonaka","year":"2014","journal-title":"Auris Nasus Larynx."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.02.049","article-title":"Mepolizumab-responsive kimura disease","volume":"9","author":"Kinoshita","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04873-0","article-title":"Successful treatment of kimura disease with benralizumab","volume":"101","author":"Szeto","year":"2022","journal-title":"Ann Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/SAP.0000000000003106","article-title":"Kimura disease of the thigh treated with surgical excision and dupilumab","volume":"88","author":"Huang","year":"2022","journal-title":"Ann Plast Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5885","article-title":"Treatment of kimura disease with dupilumab","volume":"158","author":"Teraki","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1997.tb01562.x","article-title":"In vivo expression of IL-4, IL-5, IL-13 and IFN-gamma mRNAs in peripheral blood mononuclear cells and effect of cyclosporin a in a patient with kimura's disease","volume":"137","author":"Katagiri","year":"1997","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2004.04.030","article-title":"Hematoserological analysis of kimura's disease for optimal treatment","volume":"132","author":"Sakamoto","year":"2005","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discovery"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1084879\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T07:46:42Z","timestamp":1671004002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1084879\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2022.1084879"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1084879","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"article-number":"1084879"}}